Kymera Therapeutics
KYMR

$45.40

2.58%

Market Cap: $2.93B

About: Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.

Employees: 181

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,686 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

38% more call options, than puts

Call options by funds: $961K | Put options by funds: $698K

16% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 50

0% more funds holding in top 10

Funds holding in top 10: 7 [Q1] → 7 (+0) [Q2]

0.86% less ownership

Funds ownership: 110.65% [Q1] → 109.79% (-0.86%) [Q2]

3% less funds holding

Funds holding: 161 [Q1] → 156 (-5) [Q2]

16% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 31

26% less capital invested

Capital invested by funds: $2.72B [Q1] → $2.01B (-$707M) [Q2]

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$36

21%

downside

Avg. target

$47

4%

upside

High target

$65

43%

upside

6 analyst ratings

3 positive

50%

3 neutral

50%

0 negative

0%

Wolfe Research Andy Chen 67% 1-year accuracy 6 / 9 met price target	43%upside $65	Outperform Upgraded	26 Aug 2024
Morgan Stanley James Quigley 0 / 0 met price target	1%downside $45	Equal-Weight Maintained	14 Aug 2024
Wells Fargo Derek Archila 53% 1-year accuracy 16 / 30 met price target	16%downside $38	Equal-Weight Maintained	12 Aug 2024
Oppenheimer Jeff Jones 75% 1-year accuracy 18 / 24 met price target	15%upside $52	Outperform Maintained	10 Jul 2024
B. Riley Securities Kalpit Patel 38% 1-year accuracy 5 / 13 met price target	21%downside $36	Neutral Maintained	9 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 7 articles about KYMR published over the past 30 days

Zacks Investment Research

Why Is Kymera Therapeutics (KYMR) Up 10.9% Since Last Earnings Report?

Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock?

Why Is Kymera Therapeutics (KYMR) Up 10.9% Since Last Earnings Report?

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

WATERTOWN, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats and presentations at the following upcoming investor events:

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

WATERTOWN, Mass., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the closing of its upsized underwritten public offering of $225 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera sold and issued 2,830,533 shares of its common stock, which includes 828,220 shares sold and issued upon the full exercise by the underwriters of their option to purchase additional shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 3,519,159 shares of its common stock in the offering. The shares of common stock were sold at a public offering price of $40.75 per share and the pre-funded warrants were sold at a public offering price of $40.7499 per pre-funded warrant, which represents the per share public offering price of each share of common stock, less the $0.0001 per share exercise price for each pre-funded warrant. The gross proceeds to Kymera from the offering were approximately $258.75 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Kymera.

Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Zacks Investment Research

Kymera (KYMR) to Raise $225 Million Through Offering of Shares

Kymera (KYMR) is in the process of selling approximately 2 million shares of common stock at a public offering price of $40.75 per share, along with pre-funded warrants to purchase 3,519,159 shares in the offering.

Kymera (KYMR) to Raise $225 Million Through Offering of Shares

Kymera Therapeutics Announces Pricing of $225 Million Public Offering

WATERTOWN, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the pricing of its underwritten public offering of $225 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera is selling 2,002,313 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 3,519,159 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $40.75 per share and the pre-funded warrants are being sold at a public offering price of $40.7499 per pre-funded warrant, which represents the per share public offering price of each share of common stock, less the $0.0001 per share exercise price for each pre-funded warrant. In addition, Kymera has granted the underwriters a 30-day option to purchase up to an additional 828,220 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The gross proceeds to Kymera from the offering are expected to be approximately $225 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Kymera, excluding the exercise of any pre-funded warrants and assuming no exercise of the underwriters' option to purchase additional shares. All of the securities being sold in this offering are being offered by Kymera. The offering is expected to close on August 21, 2024, subject to the satisfaction of customary closing conditions.

Kymera Therapeutics Announces Pricing of $225 Million Public Offering

Kymera Therapeutics Announces Proposed Public Offering

WATERTOWN, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that it has commenced an underwritten public offering of $200.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in this offering are being offered by Kymera. In addition, Kymera intends to grant the underwriters a 30-day option to purchase up to an additional $30.0 million of shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Kymera Therapeutics Announces Proposed Public Offering

Kymera Therapeutics, Inc. (KYMR) Q2 2024 Earnings Call Transcript

Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q2 2024 Earnings Conference Call August 7, 2024 8:30 AM ET Company Participants Justine Koenigsberg - Vice President, Investor Relations Nello Mainolfi - Founder, President & CEO Jared Gollob - Chief Medical Officer Bruce Jacobs - Chief Financial Officer Conference Call Participants Eric Joseph - J.P. Morgan Jeff Jones - Oppenheimer Kelly Shi - Jefferies Vikram Purohit - Morgan Stanley Brad Canino - Stifel Nicolaus Marc Frahm - TD Cowen Kalpit Patel - B.

Kymera Therapeutics, Inc. (KYMR) Q2 2024 Earnings Call Transcript

Zacks Investment Research

Kymera (KYMR) Q2 Loss Narrower Than Expected, Pipeline in Focus

Kymera (KYMR) reports a narrower-than-expected loss in the second quarter. The company expects the current cash balance to provide a runway into the first half of 2027.

Kymera (KYMR) Q2 Loss Narrower Than Expected, Pipeline in Focus

Zacks Investment Research

Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates

Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.67 per share a year ago.

Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates

Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7

Watertown, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report second quarter 2024 financial results on August 7, 2024, and will host a conference call at 8:30 a.m. ET.

Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7

See News Rankings